Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

RAPP

Rapport Therapeutics Inc.

Jul 03 • 03:26PM ET

24.00

Dollar change -1.01
Percentage change -4.04	%

Healthcare • Biotechnology • USA • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: MNTL

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	45.53%	Shs Outstand	35.38M	Perf Week	3.18%
Market Cap	823.68M	Forward P/E	-	EPS next Y	-	Insider Trans	4.01%	Shs Float	18.69M	Perf Month	-
Income	-	PEG	-	EPS next Q	-0.60	Inst Own	12.52%	Short Float	1.25%	Perf Quarter	-
Sales	-	P/S	-	EPS this Y	-	Inst Trans	-	Short Ratio	0.64	Perf Half Y	-
Book/sh	-1.12	P/B	-	EPS next Y	-	ROA	-	Short Interest	0.23M	Perf Year	-
Cash/sh	5.63	P/C	4.26	EPS next 5Y	-	ROE	-	52W Range	18.00 - 27.11	Perf YTD	15.38%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-	52W High	-11.47%	Beta	-
Dividend TTM	-	Quick Ratio	20.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	33.33%	ATR (14)	3.30
Dividend Ex-Date	-	Current Ratio	20.10	EPS Y/Y TTM	-	Oper. Margin	-	RSI (14)	-	Volatility	10.93% -
Employees	52	Debt/Eq	0.01	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	35.00
Option/Short	No / Yes	LT Debt/Eq	0.01	EPS Q/Q	-	Payout	-	Rel Volume	0.68	Prev Close	25.01
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	May 29	Avg Volume	367.46K	Price	24.00
SMA20	2.58%	SMA50	2.58%	SMA200	2.58%	Trades		Volume	248,079	Change	-4.04%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-24	Initiated	TD Cowen	Buy
Jul-02-24	Initiated	Stifel	Buy	$35
Jul-02-24	Initiated	Jefferies	Buy	$35

Jun-12-24 04:01PM	Rapport Therapeutics Announces Closing of $174 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares and Concurrent Private Placement (GlobeNewswire) +9.02%
Jun-06-24 06:54PM	Rapport Therapeutics Announces Pricing of Initial Public Offering (GlobeNewswire)

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
HEALY JAMES	Director	Jul 01 '24	Buy	24.52	44,032	1,079,575	40,851	Jul 03 08:04 PM
HEALY JAMES	Director	Jun 10 '24	Buy	17.00	558,824	9,500,008	1,863,327	Jun 10 07:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RAPP

Rapport Therapeutics Inc.

Upgrade your FINVIZ experience